Health Catalyst Inc (HCAT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Health Catalyst Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.20 $ — 43% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 19.9%
- Exp. sales growth 3Y > 5% -10.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -10.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -8.7%
- Expected return > 10% -10.4%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 4.0% failed
- More than 10% revenue growth is expected for the coming year -6.2% failed
- Share count grows by less than 3% a year 8.9% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1.4% failed
- Gross margin at 40% or higher and without meaningful erosion 33.5% failed
- Goodwill from acquisitions does not grow faster than revenue 41.6% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 348 m passed
- Return on capital at 15% or higher, or up versus two years ago -8.7% failed
- Insiders hold at least 10% or are net buyers 5.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 2.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.04 | -0.05 – 0.22 | 267 | -76.7% | 6 |
| 12/31/2027 | 0.09 | -0.07 – 0.52 | 250 | 119.6% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.05 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.33 | – | 80 | 6.00 | -26.00 | -4 | -8 |
| 2025: Q1 | -0.35 | – | 79 | 6.30 | -29.90 | 0 | 0 |
| 2025: Q2 | -0.59 | – | 81 | 6.30 | -50.80 | -9 | -9 |
| 2025: Q3 | -0.32 | – | 76 | 0.00 | -29.10 | -1 | -5 |
| 2025: Q4 | -1.28 | – | 75 | -6.20 | -121.90 | 10 | 10 |
| 2026: Q1 | -1.53 | – | 71 | -10.90 | -156.90 | 19 | 14 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 73 | -46 | -47 | -1.69 | -37 | -259 | 110 |
| 2018 | 113 | -60 | -62 | -2.23 | -40 | -375 | 111 |
| 2019 | 155 | -55 | -60 | -3.21 | -32 | 201 | 302 |
| 2020 | 189 | -96 | -115 | -2.91 | -26 | 276 | 578 |
| 2021 | 242 | -144 | -153 | -3.23 | -23 | 522 | 832 |
| 2022 | 276 | -140 | -137 | -2.54 | -35 | 425 | 752 |
| 2023 | 296 | -127 | -118 | -2.09 | -33 | 367 | 702 |
| 2024 | 307 | -70 | -70 | -1.15 | 15 | 365 | 859 |
| 2025 | 311 | -36 | -178 | -2.55 | 1 | 246 | 503 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Health Catalyst, Inc. bietet Datenanalyse-Technologie und -Dienstleistungen für Gesundheitsorganisationen in den USA an.
| Employees | 1,200 |
|---|---|
| Headquarters | South Jordan, UT |
| Address | 10897 South River Front Parkway, 84095 South Jordan, United States |
| Phone | 801 708 6800 |
| Website | healthcatalyst.com |
| IPO Date | 25. Jul 2019 |
| ISIN | US42225T1079 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Benjamin Albert | CEO & Director | 1973 |
| Jason Alger | Chief Financial Officer | 1984 |
| Benjamin Landry | General Counsel & Secretary of the Board | 1982 |
| Kyle J. Salyers | Chief Strategy Officer & Senior VP of Corporate Development | – |
| Carrie Kozlowski OT | Chief Marketing Officer | – |
| Jeffrey P. Selander | Senior Vice President of International | – |
| Holly Rimmasch | Senior VP & Chief Clinical Officer | – |
| Linda Llewelyn | Senior Advisor | 1967 |
| Sadiqa Mahmood D.D.S., M.P.H. | GM & Senior VP of Life Sciences Business | – |
| Kristen Berry | Senior Vice President of Public Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 16. Jul 2026 | Hoggard Green Jill | Director | Other | 80,691 | 0.00 | – |
| 16. Jul 2026 | Larson-Green Julie | Director | Other | 80,691 | 0.00 | – |
| 16. Jul 2026 | Spencer Justin | Director | Other | 80,691 | 0.00 | – |
| 16. Jul 2026 | Nelson Steven H | Director | Other | 80,691 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.